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INTRODUCTION
There is an ever increasing number of poorly water-soluble active pharmaceutical ingredients (APIs) coming through the drug development pipelines. This trend toward more hydrophobic drug substances has led to greater selectivity and potency of APIs, but at the expense of physiochemical properties such as solubility and dissolution rate [1] , [2] . These properties, particularly intestinal solubility, are strongly correlated with the intestinal absorption of orally deliverable medicines and are therefore often the rate-limiting step in the absorption of these APIs. Factors which can impact the concentration of an API at the site of drug absorption, in particular, dissolution rate and crystallization kinetics can become tuneable parameters when designing oral dosage forms to optimize their bioavailability [3] . To improve the bioavailability of hydrophobic APIs, formulation scientists have developed various strategies to manipulate solubility in the gastrointestinal system. Briefly these include; (i) solubilising strategies (such as formulation with cosolvents and/or surfactants as well as inclusion into lipid-based formulations) [4] , (ii) partial size reduction strategies (such as top down or bottom up manufacture of nanoparticles) [5] , [6] and (iii) supersaturating drug delivery systems (SDDS), such as amorphous solids, crystalline salts, cocrystals, etc. [7] - [11] . Along with concentration in the gastrointestinal system, good permeability is a requirement for adequate intestinal absorption. Permeation through the gastrointestinal membranes is thought to be improved by increasing the concentration of molecularly dissolved drug [12] , [13] . Thus formulations that produce supersaturated solutions of API have significant potential to enhance oral absorption.
However, such supersaturated solutions of API are inherently unstable and result in a loss of solution concentration through crystallization. Therefore maintaining supersaturation levels of an API in the human gastrointestinal system is essential to enhance the permeability of the API.
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Crystallization from solution occurs via nucleation (formation of an initial solid) and growth (expansion of that solid). Most previous studies have focused on using polymeric additives, such as cellulose derivatives, to prolong supersaturation by inhibiting nucleation [14] - [17] . However, recently several studies have demonstrated that bile salts can also act as crystallization inhibitors for hydrophobic APIs [3] , [18] - [21] . A recent systemic study of the effects of bile salts, phospholipids, and digestive peptides, on the solution concentration of the antibiotic agent clofazimine (CFZ), showed that the presence of these amphipathic compounds has a strong influence on solution behaviour i.e. stability and concentration [22] . These findings suggest that compounds present in the gastrointestinal system have solubilizing and/or crystallization inhibitory potential, which could benefit supersaturating drug delivery systems for hydrophobic APIs. In this study, we examined the effects of phospholipids, bile salts and the digestive protein pepsin on the crystallization behaviour of CFZ.
CFZ is a weakly basic drug, with a pKa of 8.511 [23] . In its free base form (CFZB), the API is practically insoluble in neutral, aqueous media with solubility reported to be < 0.01 mg/L [24] .
CFZ is marketed as an oily suspension of the free base form of the API, called Lamprene ® [25] .
This formulation is usually administered as 50 mg capsules, which give erratic bioavailability, 45 -60 %, following oral administration in the fasted state, although administration with food can improve bioavailability by reducing the time to reach peak plasma concentration from 12 h to 8 h [25] . The extent to which CFZ dissolves is pH dependent and can be calculated from experimentally derived solubility-pH studies [22] . Being weakly basic and ionisable, CFZ readily forms pharmaceutical salts with acidic coformers [11] . While CFZB exhibits very poor aqueous solubility, salt forms can increase solution concentration in water, and in biorelevant media [11] .
However, in low pH media, solution concentration and solution stability of the protonated CFZH + 5 species is reduced through the common ion effect [22] . The concentrations of CFZ that can be reached in biorelevant media are ~30 mg/L for modified-fasted state simulated gastric fluid (mFaSSGF -pH 1.6) and ~6 mg/L for modified-fasted state simulated intestinal fluid (m-FaSSIFpH 6.5). However, the solution concentration of CFZ in m-FaSSGF and m-FaSSIF is significantly reduced in the absence of the phospholipids, bile salts and the digestive proteins present in these buffers. The effect of these amphipathic gastrointestinal compounds on the solution behaviour of CFZ is best described in previous studies [22] , [26] . Briefly, CFZ molecules are taken up into bile salt/phospholipid mixed micelles in m-FaSSIF, thus solubilising the neutral CFZ molecules. While in m-FaSSGF, CFZ binds to the digestive enzyme pepsin, which acts as a molecular carrier for the API and prevents the precipitation of CFZ hydrochloride from the low pH solution (common ion effect) [22] , [26] .
The common ion effect ultimately drives protonated CFZ molecules in solution to crystallization as a hydrochloric acid salt, CFZ hydrochloride. This phenomenon is not unique to CFZ, but rather the common ion effect is a challenge encountered for many crystalline salt forms of weakly basic APIs in low pH environments, where crystallisation occurs as a chloride salt, and for salt forms of weakly acidic APIs in high pH environments, where crystallisation occurs as a sodium salt [8] , [27] - [29] . For example, the weakly basic API promethazine exhibits the common ion effect at low pH, resulting in a reduction of solution concentration and crystallization as promethazine hydrochloride [30] . Serajuddin et al. reported a similar finding for a sodium salt of an acid drug (REV 3164; 7-chloro-5-propyl-1H,4H- [1, 2, 4] triazolo [4,3-a] quinoxaline-1,4-dione), where the solubility of the drug in water decreased upon the addition of NaCl [31] . However, the common ion effect could potentially be overcome by formulation with a crystallization inhibitor, which could slow down the rate of precipitation from solution. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   6 In this study, solid forms of CFZ were expected to dissolve in the low pH gastric environment and then precipitate from solution as CFZ hydrochloride, through the common ion effect. CFZ hydrochloride does not dissolve to any detectable extent in the presence of chloride ions, even at pH values where other salt forms of CFZ display solubility [11] . Such solid-state transformations of APIs into less soluble solid forms can compromise solution concentration in vivo and potentially bioavailability. The aim of this study was to develop a novel solid dose formulation of a CFZ salt, with a crystallization inhibitor, to prolong supersaturation in FaSSGF. A panel of potential crystallization inhibitors was screened through crystallization induction time experiments of CFZ hydrochloride where supersaturation was induced by increasing chloride concentration in the media, to mimic the common ion effect. Potential crystallization inhibitors screened included: the synthetic polymers PVP and HPMC, and the gastrointestinal (GI) components; bile acids, sodium taurocholate, and porcine bile extract, as well as lecithin (a phospholipid extract) and pepsin (a digestive enzyme), Figure 1 . The crystallization inhibitory properties of these compounds in biorelevant dissolution media were then examined as solid physical mixtures with CFZB and CFZ phosphate. 
Methods.
Preparation of clofazimine salts. CFZ salts were prepared by recrystallization of CFZ and coformer in a 1:1 molar ratio from methanol, as previously reported [11] , [22] .
Solubility of clofazimine hydrochloride. The experimental setup for the solubility measurements consisted of a thermostatic water bath, equipped with a cooling unit, a magnetic stir plate and a submersible water pump to enhance circulation in the bath. An excess of clofazimine hydrochloride was added to solutions of water or water with additives dissolved to 0.005 %. These additives included NaTc, PBE, lecithin, PBE and lecithin (4:1), NaTc and lecithin (4:1), PVP, HPMC and pepsin (0.1 mg/mL rather than 0.005 %). These suspensions were then placed in the water bath at 37℃ and stirred at 400 rpm for 24h. Following this, the solutions were filtered (using preheated syringes and syringe filters) and appropriately diluted for solubility measurement on a UV-vis spectrophotometer. All solubility measurements were carried out in triplicate. of additives (0.005 % of either NaTc, PBE, lecithin, PBE and lecithin (4:1), NaTc and lecithin (4:1), PVP and HPMC or 0.1 mg/mL solutions of pepsin) in 250 mL Duran flasks, using ultra-pure (Milli-Q) water. These solutions were prepared at 37℃ on a submersible magnetic stir plate at 400 rpm using PTFE coated magnetic stir bars (Bath A). 200 mL of this stock solution was filtered into 10 x 20 mL glass vials using either a PTFE or cellulose acetate syringe filter (25 mm, 0.2 µM). A magnetic stir bar was added to each vial before capping with a plastic screw cap, lined with PTFE.
Vials, stir bars, screw caps, syringes, needles and syringe filters were preheated to 50℃ prior to filtration. Solutions were then subjected to a second equilibrium period of 1 h at 60℃ (Bath B); before crystallization experiments were conducted (solutions containing pepsin were stirred at 40℃ due to the thermal instability of the protein). Following the second equilibrium period, vials were transferred to a third water bath (Bath C) which was set to 37℃ and 800 rpm. Once added to Bath C, 0.5 mL of each solution was discarded, leaving a volume of 19.5 mL in each vial.
Supersaturation was generated by pipetting 0.5 mL of 1 M NaCl (heated to 37℃) into each vial containing 19.5 mL of the stock solution while stirring at 800 rpm (resulting in a final concentration of NaCl of 25 mM). Crystallisation was detected using a high definition camcorder (Sony HDRXR520VE), similar to that reported previously by Mealey et al [33] . Bath C was fitted with a strip of white ultra-bright LED lights (12V IP65 Waterproof, Qbspring) to increase contrast 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 10 and aid in the detection of crystals and the 10 vials were positioned directly in front of the light strip. Once nucleation occurred, a cloudy purple/black residue was observed in the solution along with a loss of the characteristic red colour of the CFZH + solution species. Soon after nucleation, the solution in the vial would become completely colourless, Scheme 1. This process was repeated with a fresh stock solution in each case, giving a total of 20 data points for each additive investigated during induction time experiments.
Data Analysis for induction time experiments.
Where necessary, differences in the average induction time data were compared by means of a t-test. A one-way between-subjects ANOVA test was conducted using OriginPro 8 SR1 and the ANOVA statistical analysis package to compare the data (Tukey HSD test). Differences were considered significant at the 0.05 level.
Preparation of m-FaSSGF for dissolution experiments.
Modified FaSSGF was prepared consisting of pepsin (0.1 mg/mL), sodium taurocholate (80 µM), lecithin (20 µM), sodium chloride (7.2 mM) and hydrochloric acid (25 mM), as previously published [11] , [22] . Due to the instability of the protein, pepsin was only added to the solution 30 mins before dissolution experiments began.
Dissolution experiments of CFZ solid forms and potential crystallisation inhibitors as physical mixtures. Dissolution experiments were conducted in 100 mL Duran flasks containing PTFE stir bars and 100 mL of m-FaSSGF. Solutions were stirred at 150 rpm on a submersible stir plate in a water bath at 37℃. An excess of a CFZ solid form (20mg, particle size distribution of 63 -90 microns) and 5 mg of either NaTc, PBE, PBE and lecithin (4:1), NaTc and lecithin (4:1), or HPMC was added to the dissolution medium and the flask was inverted several times. Samples were then withdrawn at predetermined time intervals using preheated (40 ℃) 5 mL syringes and 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 11 hypodermic needles and then filtered using preheated (40 ℃) PTFE or cellulose acetate syringe filters (0.2 microns, 25 mm diameter, Fisher Scientific). CFZ concentration was then immediately determined using a double beam UV-vis spectrophotometer (Shimadzu, UV-1800) at a detection wavelength of 488 nm.
Growing CFZB single crystals for optical microscopy experiments. Single crystals of CFZ F I were grown in THF by solvent evaporation crystallization. Saturated solutions of CFZ F I in THF were prepared at 37℃ in 20 mL glass vials containing an excess of solute (FI) and agitated at 800 rpm over a 24 h period. These saturated solutions were then filtered using preheated PTFE syringe filters (25 mm, 0.2 µM) into clean, preheated vials. The solution was allowed to cool at to room temperature and the top of the vial was covered with aluminium foil into which several pin holes were made. Single crystals were harvested after cooling and evaporation of one week.
Optical microscopy experiments to monitor solution-mediated transformation of CFZB into
CFZHCl. An inverted light optical microscope (Olympus IX53) integrated with Olympus SC100 camera combined with a PC with image/video capture using Olympus Stream Essentials software was 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   12 controlled water bath at 37℃ and 400 rpm. Samples were removed, filtered and characterized via either SEM or PXRD at various time points.
Scanning electron microscopy (SEM). SEM imaging was performed using a JEOL CarryScope scanning electron microscope JCM-5700. Samples were mounted on aluminium stubs with carbon tape tabs and coated by an ultrathin gold layer prior to analysis, using a gold sputterer (EMITECH K55) and the particles were imaged at a voltage of 5 kV.
Powder X-ray Diffraction (PXRD). Reflection PXRD was performed using an Empyrean diffractometer (PANalytical, Phillips) with Cu Kα 1,2 radiation (γ = 1.5406 Å) operating at 40 kV and 40 mA and at room temperature. Samples were scanned from 4º to 35º (2θ) with 0.0131º (2θ) step size and 48.195 seconds per step, on a flat stage that was spinning at 4 rpm.
RESULTS AND DISCUSSION:
The common ion effect is a problem for poorly soluble ionisable APIs because where these API form sodium or chloride salts, the common ion effect causes them to crystallize out of solution in the presence of Cl -and Na + ions [8] , [31] , [34] - [36] . The resulting chloride or sodium salt forms of the drug are practically insoluble in solutions that contain their respective counterions. This is a problem for oral delivery, as the gastrointestinal system has a high NaCl concentration.
Furthermore, if alternative salt forms of these APIs are prepared, they will dissolve in the presence of these chloride or sodium ions, only to rapidly crystallize out of solution as the poorly soluble sodium or chloride salt forms. The common ion effect for CFZ in biorelevant media was previously highlighted in a recently published study by our group [11] . In this study, several salt forms of CFZ were prepared, of which CFZ phosphate showed the greatest improvement in solution behaviour but as described above, in FaSSGF, it crystallized from solution as CFZ hydrochloride. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 13 Solution Mediated Transformation of CFZB (F I) into CFZ hydrochloride. When an excess of CFZB or any salt form of CFZ is added to low pH chloride media, e.g. FaSSGF, the residual solid remaining after the dissolution experiments is primarily the CFZ hydrochloride salt [11] , [24] . This crystallization of CFZ from solution is driven by the common ion effect and results in the eventual conversion of the entire solid administered into CFZ hydrochloride. This solution- 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Screening the impact of polymers, bile salts and pepsin on the crystallization of CFZ hydrochloride in conditions of high chloride concentration. The driving force for the common ion effect for weakly basic ionisable APIs is an increase in counterion concentration, which shifts the solubility equilibrium of the dissociated reaction to favour crystallization of the solid salt form of the API. The use of synthetic polymers, and recently of bile salts, to inhibit the crystallization of hydrophobic APIs is well described in the literature [3] , [14] - [17] , [21] , [37] , [38] . Induction time experiments were employed here to identify compounds which could slow down this crystallization of CFZ hydrochloride from solution. The panel of potential crystallization inhibitors screened included PVP and HPMC, lecithin, NaTc, porcine bile extract and porcine pepsin, Figure   1 . To mimic the common ion effect observed in the human gastric system, supersaturation was generated by titrating NaCl into aqueous solutions of CFZ hydrochloride, to a final sodium chloride concentration of 25 mM (Scheme 1). As previously mentioned CFZ hydrochloride does not dissolve to any detectable extent in 25 mM NaCl (detection limit 0.1 mg/L), thus traditional supersaturation ratios were not employed in this study. However, the level of supersaturation was 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Scheme 1: Summary of induction time procedure; (1) Undersaturated solutions of CFZ solid forms (CFZ hydrochloride or CFZ phosphate) were prepared in the presence or absence of potential crystallization inhibitors; (2) 0.5 mL of 0.1 M NaCl was titrated into these solutions to induce supersaturation through the common ion effect; (3) these vials were stirred in front of a high definition camcorder to detect the time of crystal formation (induction time). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 This complements our previous study which shows how solution concentration and stability of CFZH + at pH 1.6 (in 25 mM HCl) depends on the presence and concentration of NaTc, lecithin, and pepsin in the system [22] . These results explain that the underlying mechanism for this manipulation of solution behaviour was through interference with the crystallization kinetics of CFZ hydrochloride from these solutions, with the exception of pepsin. The interference of pepsin with the crystallization of CFZ is more likely through a protein-drug binding interaction, which is discussed in a previous study [26] . [21] , which showed how the crystallization of hydrophobic drugs can be slowed and in some cases prevented by the presence of NaTc and other bile acids [3] , [18] - [21] . The enhanced induction time observed here in the presence of the bile salt mixture, PBE, compared to NaTc alone (Figure 3b) [21] . Here it was also observed that the solutions of a single bile salt (NaTc) are better at inhibiting the crystallization of CFZ hydrochloride compared to the combination of lecithin and NaTc (Figure 3b) . A mixture of bile salts (PBE) is better at inhibiting the crystallization of CFZ hydrochloride compared to NaTc alone (Figure 3b ) but similar to NaTc alone, the ability of PBE to inhibit nucleation is diminished in the presence of phospholipids (Figure 3b) . In general, in the literature, bile salts are reportedly able to prolong the lifetime of 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 22 Monitoring of the heterogeneous nucleation of CFZ hydrochloride onto the dissolving surface of CFZB. Given that NaTc, PBE, NaTc + lecithin, PBE + lecithin and HPMC each prevented the crystallization of CFZ hydrochloride during the induction time studies (Figure 3 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 59 60 Highlighted by a red border in Figure 5 is a region of the CFZB crystal, where circular arrangements of CFZ hydrochloride crystals have nucleated onto the surface of the free base. As CFZB dissolved in 25 mM HCl, the surface of the dissolving crystals appears to provide a template onto which the HCl salt can nucleate and grow. From these initial nucleation sites, CFZ hydrochloride then grows to expand and cover the entire surface of the CFZB crystals. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 59 60 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 27 crystallisation inhibition in supersaturating drug delivery systems, but in the case of ionisable drugs which exhibit poor solubility and are subject to the common ion effect, such as clofazimine, solution mediated solid-state transformations can negate the crystallisation inhibition properties of additives and/or endogenous components of the GI tract. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   32 For 
Synopsis
The presence of crystallisation inhibitors, for example, polymers, bile salts and phospholipids, in gastrointestinal media can inhibit crystallisation in supersaturating drug delivery systems. However, in the case of ionisable drugs which exhibit poor solubility and are subject to the common ion effect, such as clofazimine, solution mediated solid-state transformations can negate their crystallisation inhibition properties. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
